PBHPrestige Consumer Healthcare Inc.

Pharmaceutical Preparations

Revenue: $1.1B; 4.3% YoY
Operating margin: 28.4%; 4.0% YoY
EBITDA: $341M; 7.2% YoY
Market cap: $2.3B
Employees: 890; $1M revenue each
Net debt / EBITDA: 2.7×; $905M net debt
AI in 10-K: 2.4; mentions per 10K words

Takeover score 1 of 13

Fixable underperformance 0 of 7

TSR below peersNo
0 of 5 years
3+ of last 5 years
High CEO pay despite TSRNo
$6M median
Median CEO pay ≥ $15M while TSR trails
Earnings not backed by cashNo
135% of net income
Cash flow under 80% of net income
Dilutive SBCNo
1% of revenue
Over 10% of revenue
Payouts exceed cash flowNo
61% of cash flow
Buybacks + dividends over cash flow
Goodwill-heavyNo
14% of assets
Over 40% of assets
Shareholder dissentNo
—
Any vote under 80% support

Buyer economics 1 of 4

Low revenue per employeeNo
$1M · 82nd pct
Bottom quartile of its SIC industry
Quiet on AINo
2.4 per 10K words · 62nd pct
Bottom quartile of AI mentions in 10-Ks
Net cashNo
2.7× EBITDA net debt
More cash than debt, positive EBITDA
Buyout-sizedYes
$2.3B market cap
Market cap $500M–$5B

Catalysts 0 of 2

Active 13DNo
0 filings
Active-intent 13D in 18 months
Net insider sellingNo
−$424K net
Net sales over $10M in 12 months

Financials

Metric	FY2022	FY2023	FY2024	FY2025	FY2026	YoY	Trend
Revenue	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	4.3%
Operating income	$330M	−$22M	$342M	$337M	$309M	8.1%
Net income	$205M	−$82M	$209M	$215M	$190M	11%
Operating cash flow	$260M	$230M	$249M	$252M	$258M	2.4%
Capex	$10M	$8M	$10M	$8M	$11M	36%
Stock-based comp	$9M	$12M	$14M	$11M	$11M	2.9%
Buybacks	$0	$50M	$25M	$52M	$156M	203%

Deal filings

None.

13D filers

None on file.

Insider trading

Open-market buys, 12 mo: $0 · 0
Open-market sells, 12 mo: $424K · 8
Net: −$424K

Pay vs performance

Year	CEO total comp	Comp actually paid	TSR (indexed)	Peer TSR
FY2026	$6M	$826K	134	70
FY2025	$6M	$8M	195	114
FY2024	$6M	$10M	165	100
FY2023	$6M	$10M	142	88
FY2022	$6M	$10M	120	100